Finished product reference

Charcoal Activated

Suspension · Oral · 200 mg/1mL · 250 mL

List code
51252
Pharmacologic class
Adsorbent; gastrointestinal decontaminant (antidote)

What it is and how it works

Activated charcoal is a highly porous form of carbon with a very large surface area that adsorbs many drugs and toxins in the gastrointestinal tract, preventing their absorption. Repeated doses can also enhance elimination of some drugs by interrupting enterohepatic circulation and ‘gut dialysis’.

Indications

Acute oral poisoning or overdose with substances adsorbed by charcoal, ideally within 1 hour of ingestion; multiple-dose therapy for selected drugs (e.g. carbamazepine, dapsone, phenobarbital, quinine, theophylline). Low-dose tablets are also used for flatulence and mild diarrhoea.

Dosage and administration (summary)

Poisoning (adults): single dose of 50 g (25–100 g) by mouth or nasogastric tube as an aqueous suspension; multiple-dose regimen typically 50 g every 4 hours or 25 g every 2 hours according to protocol.

Contraindications

Unprotected airway (reduced consciousness without intubation); gastrointestinal obstruction, perforation or ileus; ingestion of corrosives (acids, alkalis) or hydrocarbons with high aspiration risk.

Warnings and precautions

Ineffective for alcohols, glycols, iron, lithium, cyanide and other metals, strong acids and alkalis. Aspiration may cause serious pneumonitis; vomiting and constipation are common, and stools turn black. It adsorbs oral medicines and antidotes given concurrently (e.g. oral acetylcysteine) — separate administration.

Pregnancy

Not absorbed systemically; may be used in pregnancy when indicated.

Storage and supply

Store below 25 °C in a tightly closed container, away from strong odours and volatile substances.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.

Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.

Tell us the quantity, the market and the timing.

Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.

Telephone+98 21 8888 3325 · office hours 09:00–17:00, Tehran
OfficeHaniya Parsan Darou, 3rd floor, No. 326, Zafar Street, Africa Boulevard, Tehran 1968734974, Iran
Emailcontact@hanpars.com